Open Nav

Immunic AG

  • Daniel Vitt, Immunic AG

Preparation of potential series B

  • Date:Wednesday, October 17
  • Time:11:00 AM - 11:15 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Immunic is a specialist for best-in-class oral therapies for chronic inflammatory and autoimmune diseases. The company has two products in development with IMU-838 currently in phase 2b testing in patients with ulcerative colitis. The second program, IMU-935, is aiming to be tested in a first in man clinical phase 1 trial early next year. This trial will also test IMU-935 in a patient cohort with psoriasis. Within the next 2-3 years, Immunic plans to deliver multiple read-outs of clinical therapeutic efficacy for both products.
  • Company
  • Company HQ City:Planegg-Martinsried (Munich)
  • Company HQ Country:Germany
  • CEO/Top Company Official:Dr. Daniel Vitt
  • Year Founded:2016
  • Main Therapeutic Focus:Inflammation
  • Lead Product in Development :IMU-838
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Previous and Current Investors:LSP, Omega, LCP, fund+, Bayern Kapital, IBG/bmp, HTGF
  • Size of Last Investment Round:EUR 31.7
  • Total Amount Raised to Date, In All Rounds:EUR 31.7
Daniel Vitt
Immunic AG